Almost recently, novel targeted therapeutic strategies including anti-EGFR agents, such as monoclonal antibodies (cetuximab) and small molecules (gefitinib, erlotinib) have been approved for the treatment in some types of EGFR-dependent cancers, such as colon or lung and pancreatic (Barder et al. 2004; Jensen et al. 2006; Krempien et al. 2005). The gene discussed is EGFR; the disease is cancer.